lascondes_28_03

74 / 154

400
5-aminolevulinic acid for resection of malignant glioma: a
randomised controlled multicentre phase III trial. Lancet Oncol.
mayo de 2006;7(5):392-401.
24. Stummer W, Reulen H-J, Meinel T, Pichlmeier U, Schumacher W,
Tonn J-C, et al. Extent of resection and survival in glioblastoma
multiforme: identification of and adjustment for bias.
Neurosurgery. marzo de 2008;62(3):564-576-576.
25. Stummer W, Tonn J-C, Mehdorn HM, Nestler U, Franz K, Goetz C,
et al. Counterbalancing risks and gains from extended resections
in malignant glioma surgery: a supplemental analysis from
the randomized 5-aminolevulinic acid glioma resection study.
Clinical article. J Neurosurg. marzo de 2011;114(3):613-23.
26. YungWK, PradosMD, Yaya-Tur R, Rosenfeld SS, BradaM, Friedman
HS, et al. Multicenter phase II trial of temozolomide in patients
with anaplastic astrocytoma or anaplastic oligoastrocytoma at
first relapse. Temodal Brain Tumor Group. J Clin Oncol Off J Am
Soc Clin Oncol. septiembre de 1999;17(9):2762-71.
27. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB,
Janzer RC, et al. Effects of radiotherapy with concomitant and
adjuvant temozolomide versus radiotherapy alone on survival in
glioblastoma in a randomised phase III study: 5-year analysis of
the EORTC-NCIC trial. Lancet Oncol. mayo de 2009;10(5):459-
66.
28. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi M, Jaeckle KA, et
al. RTOG 0525: A randomized phase III trial comparing standard
adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule
in newly diagnosed glioblastoma (GBM). J Clin Oncol [Internet].
2011 [citado 13 de diciembre de 2016];29: 2011 (suppl; abstr
2006)(suppl; abstr 2006). Disponible en: http://meetinglibrary.
29. Minniti G, De Sanctis V, Muni R, Filippone F, Bozzao A, Valeriani
M, et al. Radiotherapy plus concomitant and adjuvant
temozolomide for glioblastoma in elderly patients. J Neurooncol.
mayo de 2008;88(1):97-103.
30. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G,
Simon M, et al. Temozolomide chemotherapy alone versus
radiotherapy alone for malignant astrocytoma in the elderly:
the NOA-08 randomised, phase 3 trial. Lancet Oncol. julio de
2012;13(7):707-15.
31. WickW, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer
F, et al. NOA-04 randomized phase III trial of sequential
radiochemotherapy of anaplastic glioma with procarbazine,
lomustine, and vincristine or temozolomide. J Clin Oncol Off J
Am Soc Clin Oncol. 10 de diciembre de 2009;27(35):5874-80.
32. Van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM,
Kouwenhoven MCM, Delattre J-Y, et al. Adjuvant procarbazine,
lomustine, and vincristine chemotherapy in newly diagnosed
anaplastic oligodendroglioma: long-term follow-up of EORTC
brain tumor group study 26951. J Clin Oncol Off J Am Soc Clin
Oncol. 20 de enero de 2013;31(3):344-50.
33. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE,
et al. Bevacizumab alone and in combination with irinotecan in
recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol. 1 de
octubre de 2009;27(28):4733-40.
34. Gilbert MR. Antiangiogenic Therapy for Glioblastoma: Complex
Biology and Complicated Results. J Clin Oncol Off J Am Soc Clin
Oncol. 10 de mayo de 2016;34(14):1567-9.
35. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT,
Vogelbaum MA, et al. A randomized trial of bevacizumab for
newly diagnosed glioblastoma. N Engl J Med. 20 de febrero de
2014;370(8):699-708.
36. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa
R, et al. Bevacizumab plus radiotherapy-temozolomide for
newly diagnosed glioblastoma. N Engl J Med. 20 de febrero de
2014;370(8):709-22.
37. Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL,
et al. Patients With Proneural Glioblastoma May Derive Overall
Survival Benefit From the Addition of Bevacizumab to First-
Line Radiotherapy and Temozolomide: Retrospective Analysis
of the AVAglio Trial. J Clin Oncol Off J Am Soc Clin Oncol. 1 de
septiembre de 2015;33(25):2735-44.
38. Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P,
Goldbrunner R, et al. Bevacizumab Plus Irinotecan Versus
Temozolomide in Newly Diagnosed O6-Methylguanine-DNA
Methyltransferase Nonmethylated Glioblastoma: The
Randomized GLARIUS Trial. J Clin Oncol Off J Am Soc Clin Oncol.
10 de mayo de 2016;34(14):1611-9.
39. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B,
Taphoorn MJB, et al. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 10 de
marzo de 2005;352(10):987-96.
40. Wernicke AG, Smith AW, Taube S, Mehta MP. Glioblastoma:
Radiation treatment margins, how small is large enough? Pract
Radiat Oncol. octubre de 2016;6(5):298-305.
[REV. MED. CLIN. CONDES - 2017; 28(3) 392-400]